IP Library Patent Application 11961447
Patent Application
App. No. 11/961,447

Ophthalmic Alginate Composition Related Methods of Manufacture and Methods of Use

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
11/961,447
Abstract

The present invention is directed to an ophthalmic composition comprising alginate having a minimum of about 0% and a maximum of about 50% guluronic units bound to an adjacent guluronic unit as a percentage of the total number of monomeric units in the alginate. The composition further includes a cationic antimicrobial agent. The alginate set forth above forms less deactivating complexes with cationic antimicrobial agent, and thus, the composition has improved preservative efficacy.

Claims (17)

1 . A dry eye composition comprising an aqueous solution of alginate having a minimum of about 10% and a maximum of about 40% guluronic units bound to an adjacent guluronic unit as a percentage of the total number of monomeric units and a cationic antimicrobial agent.

2 . The dry eye composition of claim 1 , wherein the alginate is from Lessonia nigrescens seaweed.

3 . The dry eye composition of claim 1 , further comprising a polyol that is a combination of glycerin and propylene glycol.

4 . The composition of claim 1 , wherein the alginate has a concentration that is a minimum of about 0.01 wt. % to about 5 wt. % based upon the total weight of the solution.

5 . The composition of claim 1 , further comprising a polyol selected from the group consisting of glycerin, ethylene glycol, poly(ethylene glycol), propylene glycol, sorbitol, manitol and monosaccarides, disaccharides, neutral polysaccharides and oligosaccharides.

6 . The composition of claim 1 , wherein the cationic antimicrobial agent is selected from the group consisting of poly(hexamethylene biguanide), Alexidine, chlorhexidine, polyquaternium-1, polyquaternium-10, ammonium salts of guar, ammonium salts of chitosan, and combinations thereof.

7 . The composition of claim 1 , wherein the cationic antimicrobial agent is Alexidine.

8 . A method of treating dry eye comprising administering to an eye a composition comprising an aqueous solution of alginate having a minimum of about 10% and a maximum of about 40% guluronic units bound to an adjacent guluronic unit as a percentage of the total number of monomeric units in the alginate and a cationic antimicrobial agent.

9 . The method of claim 8 , wherein the composition further comprises a polyol.

10 . The method of claim 8 , wherein the alginate has a concentration that is a minimum of about 0.01 wt. % and a maximum of about 5 wt. % based upon the total weight of the composition.

11 . The method of claim 8 , wherein the composition further comprises a polyol selected from the group consisting of glycerin, ethylene glycol, poly(ethylene glycol), propylene glycol, sorbitol, manitol and monosaccarides, disaccharides, neutral polysaccharides and oligosaccharides.

12 . The method of claim 8 , wherein the composition has an osmolality that is a minimum of about 200 and a maximum of about 400.

13 . The method of claim 8 , wherein the polyol comprises a combination of glycerin and propylene glycol.

14 . The method of claim 14 , wherein the cationic antimicrobial agent is selected from the group consisting of poly(hexamethylene biguanide), Alexidine, chlorhexidine, polyquatemium-1, polyquaternium-10, quaternary ammonium salts of guar, quaternary ammonium salts of chitosan, and combinations thereof.

15 . The method of claim 18 , wherein the cationic antimicrobial agent is Alexidine.

16 . The method of claim 8 , wherein the cationic antimicrobial agent is polyquaternium-1 or polyquaternium-10.

17 . A method of manufacturing an ophthalmic composition comprising combining in an aqueous solution ophthalmically pure alginate having a minimum of about 0% and a maximum of about 50% guluronic units bound to an adjacent guluronic unit as a percentage of the total number of monomeric units, and a cationic antimicrobial agent.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 20, 2007
From: JANI, DHARMENDRA M.; MAIER, STEPHEN E.
To: BAUSCH & LOMB INCORPORATED
Reel/Frame 020277/0665 →